XM nie świadczy usług obywatelom Stanów Zjednoczonych.
G
G

GSK


Wiadomości

GSK's injectable HIV drug shows promise over daily pills

GSK's injectable HIV drug shows promise over daily pills Feb 21 (Reuters) - British drugmaker GSK GSK.L said on Wednesday its long-acting injectable HIV therapy showed promise in keeping the viral load suppressed compared to daily oral treatment, especially in individuals facing challenges with pill intake. The interim analysis of a late-stage trial on the therapy known as Cabenuva demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals
G
P

GSK completes acquisition of Aiolos Bio for up to $1.4 bln

GSK completes acquisition of Aiolos Bio for up to $1.4 bln LONDON, Feb 15 (Reuters) - GSK GSK.L said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions. GSK will pay $1 billion upfront and up to $400 million in success-based milestone payments. "In addition, GSK will also be responsible for success-based milestone payments as well as tiered royalties owed to Jiangsu Hengrui Pharmaceuticals Co,
G

Heineken NV, Integrafin Holdings, Kingfisher

EUROPE RESEARCH ROUNDUP-Heineken NV, Integrafin Holdings, Kingfisher Feb 15 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Heineken NV, Integrafin Holdings Plc and Kingfisher, on Thursday. HIGHLIGHTS * Heineken NV HEIN.AS : HSBC cuts to hold from buy * Integrafin Holdings Plc IHPI.L : RBC raises to outperform from sector perform * Kingfisher KGF.L : Jefferies cuts to hold from buy * Neste Oyj NESTE.HE : Barclays cuts to equal weig
A
A
B
B
B
B
C
C
C
E
E
G
G
H
H
I
K
N
N
R
S
S
S
S
T
T
W
A
A
A
A
B
P
P
S

Gsk Exercises Option To License Elsie Biotechnologies' Discovery Platform

BRIEF-Gsk Exercises Option To License Elsie Biotechnologies' Discovery Platform Feb 14 (Reuters) - GSK plc GSK.L : GSK EXERCISES OPTION TO LICENSE ELSIE BIOTECHNOLOGIES' DISCOVERY PLATFORM TO FIND AND DEVELOP NOVEL OLIGONUCLEOTIDES WILL RECEIVE A LICENSE PAYMENT AND POTENTIAL DEVELOPMENT AND COMMERCIAL MILESTONES UNDER TERMS OF AGREEMENT ELSIE COUL
G

BAE Systems, Bytes Technology Group Plc, Novo Nordisk

EUROPE RESEARCH ROUNDUP-BAE Systems, Bytes Technology Group Plc, Novo Nordisk Feb 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including BAE Systems, Bytes Technology Group Plc and Novo Nordisk, on Wednesday. HIGHLIGHTS * Acast AB (Publ) ACAST.ST : Barclays raises to overweight from equal weight * BAE Systems BAES.L : Jefferies cuts to hold from buy * Bytes Technology Group Plc BYIT.L : Jefferies cuts to hold from buy * Novo Nordisk NO
A
A
B
B
C
D
D
E
F
G
H
K
L
M
S
U
A
R
R
Y

Health Rounds: Moderna vaccine shows promise against cytomegalovirus

Health Rounds: Moderna vaccine shows promise against cytomegalovirus By Nancy Lapid Feb 13 (Reuters) - Hello Health Rounds Readers! Today we feature exiting clinical trial news as major drugmakers advance a pair of highly promising future products. A cytomegalovirus mRNA vaccine from COVID vaccine maker Moderna MRNA.O triggered the intended immune response.
G
N
S

Citi upgrades GSK to 'buy' for first time in seven years

BUZZ-Citi upgrades GSK to 'buy' for first time in seven years ** Analysts at Citi upgrade British drugmaker GSK GSK.L to "buy" for the first time in 7 years; raises target price to 21 pounds from 17 pounds ** Stock up as much as 2.7% at 1,670p ** Upgrades stock on positive results from DREAMM-7 study for its multiple myeloma drug, Blenrep ** "Assum
G

Europe set for soft start ahead of US CPI

LIVE MARKETS-Europe set for soft start ahead of US CPI Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE SET FOR SOFT START AHEAD OF US CPI European shares were set to ease on Tuesday in cautious trading ahead of a highly watched U.S.
C
G
N
T
R
U

GSK's India arm slips on Q3 profit fall

BUZZ-GSK's India arm slips on Q3 profit fall ** Shares of GlaxoSmithKline Pharmaceuticals GLAX.NS fall as much as 10.6% to 2,091 rupees, lowest since Jan. 10 ** The pharma co said on Monday its consol profit before exceptional items and tax for Dec-qtr fell ~3% Y/Y ** More than 420,000 shares change hands, 1.3x its 30-day avg ** Stock eyes fifth st
G

Elisa Oyj, KBC Groep NV, L'Oreal

EUROPE RESEARCH ROUNDUP-Elisa Oyj, KBC Groep NV, L'Oreal Feb 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Elisa Oyj, KBC Groep NV and L'Oreal, on Tuesday. HIGHLIGHTS * Avanza Bank AVANZ.ST : Citigroup raises to neutral from sell * Elisa Oyj ELISA.HE : HSBC raises to buy from hold * Endomines Finland Oyj PAMPALO.HE : Evli Research cuts to sell from hold * KBC Groep NV KBC.BR : CFRA raises to hold from sell * L'Oréal OREP.PA :
A
A
C
E
E
F
G
G
H
K
L
L
L
R
S
V
V
A
Y

US lawmakers call for sanctions on China's WuXi AppTec biotech firm

US lawmakers call for sanctions on China's WuXi AppTec biotech firm By Michael Martina WASHINGTON, Feb 12 (Reuters) - The U.S. should review Chinese biotech firm WuXi AppTec and its affiliate WuXi Biologics for sanctions, a bipartisan group of lawmakers told top Biden administration officials on Monday. In a letter dated Feb. 12 and seen by Reuters, the lawmakers told Treasury Secretary Janet Yellen, Defense Secretary Lloyd Austin and Commerce Secretary Gina Raimondo that the global pharmaceutic
A
G
P

GSK India arm's Q3 profit falls on government price cap

GSK India arm's Q3 profit falls on government price cap BENGALURU, Feb 12 (Reuters) - GlaxoSmithKline Pharmaceuticals GLAX.NS , the Indian unit of the UK's GSK GSK.L , reported a 3% fall in third-quarter profit on Monday, hurt by the government's pricing cap on certain medicines. Consolidated profit before exceptional items and tax for the quarter ended Dec.
A
G

GSK Announces US FDA Fast Track Designation For Bepirovirsen

BRIEF-GSK Announces US FDA Fast Track Designation For Bepirovirsen Feb 12 (Reuters) - GSK plc GSK.L : US FDA FAST TRACK DESIGNATION FOR BEPIROVIRSEN GSK RECEIVES US FDA FAST TRACK DESIGNATION FOR BEPIROVIRSEN IN CHRONIC HEPATITIS B DESIGNATION UNDERSCORES UNMET NEED FOR MEDICINES THAT CAN ACHIEVE FUNCTIONAL CURE IN PATIENTS WITH CHRONIC HEPATITIS B
G

India economic, corporate events on Feb. 12

CORRECTED-DIARY- India economic, corporate events on Feb. 12 Removes incorrect entries for Trade Def Govt, Imports and Exports BENGALURU, Feb 12 (Reuters) - Diary of India economic, corporate events on Feb 12. ECONOMIC, CORPORATE .BSE500 EVENTS: RIC Local Start Date Local Time Indicator Name Period Reuters Poll Prior INCPIY=ECI 12 Feb 2024 17:30 CPI Inflation YY Jan 5.09% 5.69% INIP=ECI 12 Feb 2024 17:30 Industrial Output YY Dec 2.4% 2.4% INIPC=ECI 12 Feb 2024 17:30 Cumulative Ind.
B
G

Moderna shares slide on concerns over drop in RSV vaccine efficacy (Feb 9)

CORRECTED-UPDATE 1-Moderna shares slide on concerns over drop in RSV vaccine efficacy (Feb 9) Corrects paragraph 5 in Feb. 9 story to say efficacy of Pfizer's shot fell from 89% to 79% in the mid-season two, not to 49% from 67% in 17 months Feb 9 (Reuters) - Moderna MRNA.O fell as much as 7% on Friday after Wall Street analysts raised concerns over faster declines in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine when compared with rival shots from GSK GSK.L and Pfize
G
P

Moderna shares slide as longer-term data shows quick fall in RSV vaccine efficacy

Moderna shares slide as longer-term data shows quick fall in RSV vaccine efficacy Feb 9 (Reuters) - Moderna MRNA.O shares fell 6% on Friday after a longer-term analysis of a trial indicated a quicker fall in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine. At least two analysts pointed to the data, posted ahead of a conference on RSV next week, that showed a vaccine efficacy of about 63% after 8.6 months, from 84% at 3.3 months.
G
P

Moderna falls after brokerage flags concerns on RSV vaccine trial data

BUZZ-Moderna falls after brokerage flags concerns on RSV vaccine trial data ** Shares of vaccine maker Moderna MRNA.O fall 5.6% to $88.51 ** Brokerage TD Cowen says new trial data suggests Moderna's RSV vaccine's efficacy is declining quicker than GSK GSK.L and Pfizer PFE.N vaccines ** Says MRNA's vaccine 1345 saw a 25% decline after 8.6 months, wh
G
P

Pfizer's India unit set for worst day in a year on Q3 profit drop

BUZZ-Pfizer's India unit set for worst day in a year on Q3 profit drop ** Shares of Pfizer Ltd PFIZ.NS , Indian unit of Pfizer Inc PFE.N , down 3.7% at 4,347.85 rupees ** Stock on track for worst day since Feb. 13, 2023, and to fall for a third straight session ** Co's Q3 profit fell ~14% YoY ** Rivals Abbott India ABOT.NS and GlaxoSmithKline Pharm
A
G
P

Adyen, AstraZeneca, Bellway

EUROPE RESEARCH ROUNDUP-Adyen, AstraZeneca, Bellway Feb 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Adyen, AstraZeneca and Bellway, on Friday. HIGHLIGHTS * Adyen NV ADYEN.AS : TD Cowen raises to outperform from market perform * AstraZeneca AZN.L : Deutsche Bank cuts to sell from hold * Bellway Plc BWY.L : Peel Hunt cuts to hold from buy * Boliden AB BOL.ST : Berenberg raises to hold from sell * Eutelsat Communications ETL.PA :
A
A
B
B
B
B
B
C
C
D
E
E
E
E
G
H
H
H
K
N
P
P
R
S
S
S
A
A
B
B

Arrowhead Pharma down on bigger-than-expected Q1 loss

BUZZ-Arrowhead Pharma down on bigger-than-expected Q1 loss ** Shares of drug developer Arrowhead Pharmaceuticals ARWR.O fall 5.7% to $ 31.3 premarket ** Arrowhead reported a first-quarter net loss of $1.24/share vs analysts' estimates of loss of 82 cents per share - LSEG data ** ARWR's revenue plunged 94% to $3.6 mln from a year ago ** Revenue for the Sept-Dec quarter consisted primarily of revenue from partners GSK GSK.L and Takeda 4502.T , while the corresponding period in the previous year co
A
G



Warunki

Popularne aktywa

Wyłączenie odpowiedzialności: Każdy z podmiotów należących do XM Group świadczy usługę polegającą wyłącznie na realizacji zleceń i dostępie do naszej internetowej platformy transakcyjnej, umożliwiając danej osobie przeglądanie i/lub korzystanie z treści dostępnych na stronie lub za jej pośrednictwem, co nie ma na celu zmiany lub rozszerzenia tego zakresu, ani nie zmienia i nie rozszerza go. Taki dostęp i korzystanie z niego podlegają w każdej chwili: (i) Warunkom umowy, (ii) Ostrzeżeniom o ryzyku i (iii) Pełnemu wyłączeniu odpowiedzialności. Treści te są zatem podawane wyłącznie jako informacje ogólne. W szczególności należy pamiętać, że treści zawarte na naszej internetowej platformie transakcyjnej nie stanowią oferty ani zaproszenia do zawarcia jakichkolwiek transakcji na rynkach finansowych. Transakcje na każdym rynku finansowym wiążą się ze znacznym poziomem ryzyka dla twojego kapitału.

Wszystkie materiały publikowane na naszej internetowej platformie transakcyjnej są przeznaczone wyłącznie do celów edukacyjnych/informacyjnych i nie zawierają – i nie powinny być uważane za zawierające – porad ani rekomendacji dotyczących finansów, inwestycji, podatków lub transakcji, zapisu naszych cen transakcyjnych, ani też oferty lub zaproszenia do transakcji na jakichkolwiek instrumentach lub niezamówionych promocji finansowych.

Wszelkie treści pochodzące od podmiotów trzecich, jak i treści przygotowane przez XM, takie jak opinie, wiadomości, badania, analizy, ceny i inne informacje lub linki do stron podmiotów trzecich zawarte na tej stronie internetowej są udostępniane na zasadzie „tak, jak jest” jako ogólny komentarz rynkowy i nie stanowią porady inwestycyjnej. W zakresie, w jakim jakakolwiek treść jest interpretowana jako badania inwestycyjne, należy zauważyć i zaakceptować, że treść ta nie była przeznaczona i nie została przygotowana zgodnie z wymogami prawnymi mającymi na celu promowanie niezależności badań inwestycyjnych i jako taka byłaby uważana za komunikat marketingowy w świetle odpowiednich przepisów prawnych i regulacji. Upewnij się, że przeczytałeś(-aś) i rozumiesz nasze dokumenty Powiadomienie o zależnych badaniach inwestycyjnych oraz Ostrzeżenie o ryzyku, dotyczące powyższych informacji, do których można uzyskać dostęp tutaj.

Ostrzeżenie o ryzyku: Twój kapitał jest zagrożony. Produkty z zastosowaniem dźwigni mogą nie być odpowiednie dla każdego inwestora. Zapoznaj się z Ujawnieniem ryzyka.